Jeroen Schoots

Publications (10)83.27 Total impact

• Article: Meier-Gorlin syndrome: Growth and secondary sexual development of a microcephalic primordial dwarfism disorder.

  Sonja A de Munnik, Barto J Otten, Jeroen Schoots, Louise S Bicknell, Salim Aftimos, Jumana Y Al-Aama, Yolande van Bever, Michael B Bober, George F Borm, Jill Clayton-Smith, [......], Annick Toutain, Carol A Wise, Michael Wright, David L Skidmore, Mark E Samuels, Lies H Hoefsloot, Nine V A M Knoers, Han G Brunner, Andrew P Jackson, Ernie M H F Bongers
  [show abstract] [hide abstract]
  ABSTRACT: Meier-Gorlin syndrome (MGS) is a rare autosomal recessive disorder characterized by primordial dwarfism, microtia, and patellar aplasia/hypoplasia. Recently, mutations in the ORC1, ORC4, ORC6, CDT1, and CDC6 genes, encoding components of the pre-replication complex, have been identified. This complex is essential for DNA replication and therefore mutations are expected to impair cell proliferation and consequently could globally reduce growth. However, detailed growth characteristics of MGS patients have not been reported, and so this is addressed here through study of 45 MGS patients, the largest cohort worldwide. Here, we report that growth velocity (length) is impaired in MGS during pregnancy and first year of life, but, thereafter, height increases in paralleled normal reference centiles, resulting in a mean adult height of -4.5 standard deviations (SD). Height is dependent on ethnic background and underlying molecular cause, with ORC1 and ORC4 mutations causing more severe short stature and microcephaly. Growth hormone therapy (n = 9) was generally ineffective, though in two patients with significantly reduced IGF1 levels, growth was substantially improved by GH treatment, with 2SD and 3.8 SD improvement in height. Growth parameters for monitoring growth in future MGS patients are provided and as well we highlight that growth is disproportionately affected in certain structures, with growth related minor genital abnormalities (42%) and mammary hypoplasia (100%) frequently present, in addition to established effects on ears and patellar growth. © 2012 Wiley Periodicals, Inc.
  American Journal of Medical Genetics Part A 09/2012; 158A(11):2733-42. · 2.39 Impact Factor
• Source

  Available from: Conny van Ravenswaaij-Arts

  Article: A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome.

  Jorieke E H Bergman, Nicole Janssen, Almer M van der Sloot, Hermien E K de Walle, Jeroen Schoots, Nanna D Rendtorff, Lisbeth Tranebjaerg, Lies H Hoefsloot, Conny M A van Ravenswaaij-Arts, Robert M W Hofstra
  [show abstract] [hide abstract]
  ABSTRACT: CHARGE syndrome is characterized by the variable occurrence of multisensory impairment, congenital anomalies, and developmental delay, and is caused by heterozygous mutations in the CHD7 gene. Correct interpretation of CHD7 variants is essential for genetic counseling. This is particularly difficult for missense variants because most variants in the CHD7 gene are private and a functional assay is not yet available. We have therefore developed a novel classification system to predict the pathogenic effects of CHD7 missense variants that can be used in a diagnostic setting. Our classification system combines the results from two computational algorithms (PolyPhen-2 and Align-GVGD) and the prediction of a newly developed structural model of the chromo- and helicase domains of CHD7 with segregation and phenotypic data. The combination of different variables will lead to a more confident prediction of pathogenicity than was previously possible. We have used our system to classify 145 CHD7 missense variants. Our data show that pathogenic missense mutations are mainly present in the middle of the CHD7 gene, whereas benign variants are mainly clustered in the 5' and 3' regions. Finally, we show that CHD7 missense mutations are, in general, associated with a milder phenotype than truncating mutations.
  Human Mutation 04/2012; 33(8):1251-60. · 5.69 Impact Factor
• Source

  Available from: Conny van Ravenswaaij-Arts

  Article: Mutation update on the CHD7 gene involved in CHARGE syndrome.

  Nicole Janssen, Jorieke E H Bergman, Morris A Swertz, Lisbeth Tranebjaerg, Marianne Lodahl, Jeroen Schoots, Robert M W Hofstra, Conny M A van Ravenswaaij-Arts, Lies H Hoefsloot
  [show abstract] [hide abstract]
  ABSTRACT: CHD7 is a member of the chromodomain helicase DNA-binding (CHD) protein family that plays a role in transcription regulation by chromatin remodeling. Loss-of-function mutations in CHD7 are known to cause CHARGE syndrome, an autosomal-dominant malformation syndrome in which several organ systems, for example, the central nervous system, eye, ear, nose, and mediastinal organs, are variably involved. In this article, we review all the currently described CHD7 variants, including 183 new pathogenic mutations found by our laboratories. In total, we compiled 528 different pathogenic CHD7 alterations from 508 previously published patients with CHARGE syndrome and 294 unpublished patients analyzed by our laboratories. The mutations are equally distributed along the coding region of CHD7 and most are nonsense or frameshift mutations. Most mutations are unique, but we identified 94 recurrent mutations, predominantly arginine to stop codon mutations. We built a locus-specific database listing all the variants that is easily accessible at www.CHD7.org. In addition, we summarize the latest data on CHD7 expression studies, animal models, and functional studies, and we discuss the latest clinical insights into CHARGE syndrome.
  Human Mutation 03/2012; 33(8):1149-60. · 5.69 Impact Factor
• Source

  Available from: physiomics.eu

  Article: Novel NCC mutants and functional analysis in a new cohort of patients with Gitelman syndrome.

  Bob Glaudemans, Helger G Yntema, Pedro San-Cristobal, Jeroen Schoots, Rolph Pfundt, Erik-J Kamsteeg, René J Bindels, Nine V A M Knoers, Joost G Hoenderop, Lies H Hoefsloot
  [show abstract] [hide abstract]
  ABSTRACT: Gitelman syndrome (GS) is an autosomal recessive disorder characterized by hypokalemic metabolic alkalosis in conjunction with significant hypomagnesemia and hypocalciuria. The GS phenotype is caused by mutations in the solute carrier family 12, member 3 (SLC12A3) gene that encodes the thiazide-sensitive NaCl cotransporter (NCC). We analyzed DNA samples of 163 patients with a clinical suspicion of GS by direct sequencing of all 26 exons of the SLC12A3 gene. In total, 114 different mutations were identified, 31 of which have not been reported before. These novel variants include 3 deletions, 18 missense, 6 splice site and 4 nonsense mutations. We selected seven missense mutations to investigate their effect on NCC activity and plasma membrane localization by using the Xenopus laevis oocyte expression system. The Thr392Ile mutant did not display transport activity (probably class 2 mutation), while the Asn442Ser and Gln1030Arg NCC mutants showed decreased plasma membrane localization and consequently function, likely due to impaired trafficking (class 3 mutation). Even though the NaCl uptake was hampered for NCC mutants Glu121Asp, Pro751Leu, Ser475Cys and Tyr489His, the transporters reached the plasma membrane (class 4 mutation), suggesting an effect on NCC regulation or ion affinity. The present study shows the identification of 38 novel mutations in the SLC12A3 gene and provides insight into the mechanisms that regulate NCC.
  European journal of human genetics: EJHG 03/2012; 20(3):263-70. · 3.56 Impact Factor
• Article: Meier-Gorlin syndrome genotype-phenotype studies: 35 individuals with pre-replication complex gene mutations and 10 without molecular diagnosis.

  Sonja A de Munnik, Louise S Bicknell, Salim Aftimos, Jumana Y Al-Aama, Yolande van Bever, Michael B Bober, Jill Clayton-Smith, Alaa Y Edrees, Murray Feingold, Alan Fryer, [......], Annick Toutain, Carol A Wise, Michael Wright, David L Skidmore, Mark E Samuels, Lies H Hoefsloot, Nine V A M Knoers, Han G Brunner, Andrew P Jackson, Ernie M H F Bongers
  [show abstract] [hide abstract]
  ABSTRACT: Meier-Gorlin syndrome (MGS) is an autosomal recessive disorder characterized by microtia, patellar aplasia/hypoplasia, and short stature. Recently, mutations in five genes from the pre-replication complex (ORC1, ORC4, ORC6, CDT1, and CDC6), crucial in cell-cycle progression and growth, were identified in individuals with MGS. Here, we report on genotype-phenotype studies in 45 individuals with MGS (27 females, 18 males; age 3 months-47 years). Thirty-five individuals had biallelic mutations in one of the five causative pre-replication genes. No homozygous or compound heterozygous null mutations were detected. In 10 individuals, no definitive molecular diagnosis was made. The triad of microtia, absent/hypoplastic patellae, and short stature was observed in 82% of individuals with MGS. Additional frequent clinical features were mammary hypoplasia (100%) and abnormal genitalia (42%; predominantly cryptorchidism and hypoplastic labia minora/majora). One individual with ORC1 mutations only had short stature, emphasizing the highly variable clinical spectrum of MGS. Individuals with ORC1 mutations had significantly shorter stature and smaller head circumferences than individuals from other gene categories. Furthermore, compared with homozygous missense mutations, compound heterozygous mutations appeared to have a more severe effect on phenotype, causing more severe growth retardation in ORC4 and more frequently pulmonary emphysema in CDT1. A lethal phenotype was seen in four individuals with compound heterozygous ORC1 and CDT1 mutations. No other clear genotype-phenotype association was observed. Growth hormone and estrogen treatment may be of some benefit, respectively, to growth retardation and breast hypoplasia, though further studies in this patient group are needed.
  European journal of human genetics: EJHG 02/2012; 20(6):598-606. · 3.56 Impact Factor
• Article: Mutations in the pre-replication complex cause Meier-Gorlin syndrome.

  Louise S Bicknell, Ernie M H F Bongers, Andrea Leitch, Stephen Brown, Jeroen Schoots, Margaret E Harley, Salim Aftimos, Jumana Y Al-Aama, Michael Bober, Paul A J Brown, [......], Nine V A M Knoers, James Mackenzie, John M Opitz, Pierre Sarda, Alison Ross, I Karen Temple, Annick Toutain, Carol A Wise, Michael Wright, Andrew P Jackson
  [show abstract] [hide abstract]
  ABSTRACT: Meier-Gorlin syndrome (ear, patella and short-stature syndrome) is an autosomal recessive primordial dwarfism syndrome characterized by absent or hypoplastic patellae and markedly small ears¹⁻³. Both pre- and post-natal growth are impaired in this disorder, and although microcephaly is often evident, intellect is usually normal in this syndrome. We report here that individuals with this disorder show marked locus heterogeneity, and we identify mutations in five separate genes: ORC1, ORC4, ORC6, CDT1 and CDC6. All of these genes encode components of the pre-replication complex, implicating defects in replication licensing as the cause of a genetic syndrome with distinct developmental abnormalities.
  Nature Genetics 02/2011; 43(4):356-9. · 35.53 Impact Factor
• Source

  Available from: Conny van Ravenswaaij-Arts

  Article: A novel cerebello-ocular syndrome with abnormal glycosylation due to abnormalities in dolichol metabolism.

  Eva Morava, Ron A Wevers, Vincent Cantagrel, Lies H Hoefsloot, Lihadh Al-Gazali, Jeroen Schoots, Arno van Rooij, Karin Huijben, Connie M A van Ravenswaaij-Arts, Marjolein C J Jongmans, [......], Bobby G Ng, Jorieke E H Bergman, Hans van Bokhoven, Christian Körner, Dusica Babovic-Vuksanovic, Michel A Willemsen, Joseph G Gleeson, Ludwig Lehle, Arjan P M de Brouwer, Dirk J Lefeber
  [show abstract] [hide abstract]
  ABSTRACT: Cerebellar hypoplasia and slowly progressive ophthalmological symptoms are common features in patients with congenital disorders of glycosylation type I. In a group of patients with congenital disorders of glycosylation type I with unknown aetiology, we have previously described a distinct phenotype with severe, early visual impairment and variable eye malformations, including optic nerve hypoplasia, retinal coloboma, congenital cataract and glaucoma. Some of the symptoms overlapped with the phenotype in other congenital disorders of glycosylation type I subtypes, such as vermis hypoplasia, anaemia, ichtyosiform dermatitis, liver dysfunction and coagulation abnormalities. We recently identified pathogenic mutations in the SRD5A3 gene, encoding steroid 5α-reductase type 3, in a group of patients who presented with this particular phenotype and a common metabolic pattern. Here, we report on the clinical, genetic and metabolic features of 12 patients from nine families with cerebellar ataxia and congenital eye malformations diagnosed with SRD5A3-congenital disorders of glycosylation due to steroid 5α-reductase type 3 defect. This enzyme is necessary for the reduction of polyprenol to dolichol, the lipid anchor for N-glycosylation in the endoplasmic reticulum. Dolichol synthesis is an essential metabolic step in protein glycosylation. The current defect leads to a severely abnormal glycosylation state already in the early phase of the N-glycan biosynthesis pathway in the endoplasmic reticulum. We detected high expression of SRD5A3 in foetal brain tissue, especially in the cerebellum, consistent with the finding of the congenital cerebellar malformations. Based on the overlapping clinical, biochemical and genetic data in this large group of patients with congenital disorders of glycosylation, we define a novel syndrome of cerebellar ataxia associated with congenital eye malformations due to a defect in dolichol metabolism.
  Brain 11/2010; 133(11):3210-20. · 9.46 Impact Factor
• Article: Identification of a novel COCH mutation, G87W, causing autosomal dominant hearing impairment (DFNA9).

  Rob W J Collin, Robert J Pauw, Jeroen Schoots, Patrick L M Huygen, Lies H Hoefsloot, Cor W R J Cremers, Hannie Kremer
  American Journal of Medical Genetics Part A 09/2006; 140(16):1791-4. · 2.39 Impact Factor
• Source

  Available from: Paul F.M. Krabbe

  Article: Genotype-phenotype studies in nail-patella syndrome show that LMX1B mutation location is involved in the risk of developing nephropathy.

  Ernie M H F Bongers, Frans T Huysmans, Elena Levtchenko, Jacky W de Rooy, Johan G Blickman, Ronald J C Admiraal, Patrick L M Huygen, Johannes R M Cruysberg, Pauline A M P Toolens, Judith B Prins, Paul F M Krabbe, George F Borm, Jeroen Schoots, Hans van Bokhoven, Angela M F van Remortele, Lies H Hoefsloot, Albert van Kampen, Nine V A M Knoers
  [show abstract] [hide abstract]
  ABSTRACT: Nail-patella syndrome (NPS) is characterized by developmental defects of dorsal limb structures, nephropathy, and glaucoma and is caused by heterozygous mutations in the LIM homeodomain transcription factor LMX1B. In order to identify possible genotype-phenotype correlations, we performed LMX1B mutation analysis and comprehensive investigations of limb, renal, ocular, and audiological characteristics in 106 subjects from 32 NPS families. Remarkable phenotypic variability at the individual, intrafamilial, and interfamilial level was observed for different NPS manifestations. Quantitative urinanalysis revealed proteinuria in 21.3% of individuals. Microalbuminuria was detected in 21.7% of subjects without overt proteinuria. Interestingly, nephropathy appeared significantly more frequent in females. A significant association was established between the presence of clinically relevant renal involvement in an NPS patient and a positive family history of nephropathy. We identified normal-tension glaucoma (NTG) and sensorineural hearing impairment as new symptoms associated with NPS. Sequencing of LMX1B revealed 18 different mutations, including six novel variants, in 28 families. Individuals with an LMX1B mutation located in the homeodomain showed significantly more frequent and higher values of proteinuria compared to subjects carrying mutations in the LIM domains. No clear genotype-phenotype association was apparent for extrarenal manifestations. This is the first study indicating that family history of nephropathy and mutation location might be important in precipitating individual risks for developing NPS renal disease. We suggest that the NPS phenotype is broader than previously described and that NTG and hearing impairment are part of NPS. Further studies on modifier factors are needed to understand the mechanisms underlying phenotypic heterogeneity.
  European Journal of HumanGenetics 09/2005; 13(8):935-46. · 4.40 Impact Factor
• Source

  Available from: ncbi.nlm.nih.gov

  Article: Mutations in the human TBX4 gene cause small patella syndrome.

  Ernie M H F Bongers, Pascal H G Duijf, Sylvia E M van Beersum, Jeroen Schoots, Albert Van Kampen, Andreas Burckhardt, Ben C J Hamel, Frantisek Losan, Lies H Hoefsloot, Helger G Yntema, Nine V A M Knoers, Hans van Bokhoven
  [show abstract] [hide abstract]
  ABSTRACT: Small patella syndrome (SPS) is an autosomal-dominant skeletal dysplasia characterized by patellar aplasia or hypoplasia and by anomalies of the pelvis and feet, including disrupted ossification of the ischia and inferior pubic rami. We identified an SPS critical region of 5.6 cM on chromosome 17q22 by haplotype analysis. Putative loss-of-function mutations were found in a positional gene encoding T-box protein 4 (TBX4) in six families with SPS. TBX4 encodes a transcription factor with a strongly conserved DNA-binding T-box domain that is known to play a crucial role in lower limb development in chickens and mice. The present identification of heterozygous TBX4 mutations in SPS patients, together with the similar skeletal phenotype of animals lacking Tbx4, establish the importance of TBX4 in the developmental pathways of the lower limbs and the pelvis in humans.
  The American Journal of Human Genetics 07/2004; 74(6):1239-48. · 10.60 Impact Factor